Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The possibility of using MRD as a surrogate endpoint for PFS and OS in myeloma clinical trials

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the use of measurable residual disease (MRD) as a future surrogate for progression-free and overall survival (PFS; OS) in multiple myeloma clinical trials. Referencing data from 15 randomized trials featuring patients with newly diagnosed transplant-eligible, transplant-ineligible and relapsed/refractory (R/R) multiple myeloma, MRD was found to have a moderate correlation to both PFS and OS, and has the possibility to accelerate the gathering of crucial follow-up data in clinical trials. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.